Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gloria Lee

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone drivenGerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
Communications Biology|November 24, 2023
High-throughput feedback-enabled optogenetic stimulation and spectroscopy in microwell platesWilliam Benman, Saachi Datta, David Gonzalez-Martinez, et al.
Molecular Psychiatry|August 14, 2024
Tau pathology in the dorsal raphe may be a prodromal indicator of Alzheimer's diseaseSamantha R Pierson, Kimberly L Fiock, Ruixiang Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerGerhardt Attard, Alison H M Reid, Roger A'Hern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetateAlison H M Reid, Gerhardt Attard, Daniel C Danila, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone drivenGerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
Communications Biology|November 24, 2023
High-throughput feedback-enabled optogenetic stimulation and spectroscopy in microwell platesWilliam Benman, Saachi Datta, David Gonzalez-Martinez, et al.
Molecular Psychiatry|August 14, 2024
Tau pathology in the dorsal raphe may be a prodromal indicator of Alzheimer's diseaseSamantha R Pierson, Kimberly L Fiock, Ruixiang Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerGerhardt Attard, Alison H M Reid, Roger A'Hern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetateAlison H M Reid, Gerhardt Attard, Daniel C Danila, et al.
Pageof 8